Log in

NASDAQ:SAVA - Cassava Sciences Stock Price, Forecast & News

$4.26
+0.13 (+3.15 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
$3.80
Now: $4.26
$4.49
50-Day Range
$3.26
MA: $5.93
$8.25
52-Week Range
$1.00
Now: $4.26
$10.95
Volume647,884 shs
Average Volume858,400 shs
Market Capitalization$73.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.81
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SAVA
CUSIPN/A
CIKN/A
Phone512-501-2444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.14 per share

Profitability

Net Income$-6,560,000.00

Miscellaneous

Employees9
Market Cap$73.36 million
Next Earnings Date5/4/2020 (Estimated)
OptionableNot Optionable

Receive SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter.


Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions

How has Cassava Sciences' stock been impacted by COVID-19 (Coronavirus)?

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SAVA shares have increased by 0.5% and is now trading at $4.26. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cassava Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cassava Sciences.

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Cassava Sciences.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences Inc (NASDAQ:SAVA) announced its earnings results on Thursday, March, 26th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. View Cassava Sciences' earnings history.

When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?

Cassava Sciences's stock reverse split on the morning of Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SAVA?

2 equities research analysts have issued twelve-month price objectives for Cassava Sciences' shares. Their forecasts range from $6.00 to $12.00. On average, they expect Cassava Sciences' share price to reach $9.00 in the next twelve months. This suggests a possible upside of 111.3% from the stock's current price. View analysts' price targets for Cassava Sciences.

What are Wall Street analysts saying about Cassava Sciences stock?

Here are some recent quotes from research analysts about Cassava Sciences stock:
  • 1. According to Zacks Investment Research, "Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States. " (1/25/2020)
  • 2. Maxim Group analysts commented, "Cassava announced the initiation of Phase 2b for its lead therapeutic candidate PTI-125 in mild-moderate Alzheimer’s disease (AD). The first two patients of the trial have been dosed. The Phase 2b initiation follows positive Phase 2a results (see note 9/9, LINK) in which a 100% responder rate and statistically significant reductions (p<0.001) in key AD biomarkers were noted, including an improved cerebrospinal fluid (CSF) P-tau to Aβ42 ratio (p<0.001), which has been found to correlate with cognitive deficiencies."" (9/18/2019)
  • 3. HC Wainwright analysts commented, "Our $3 PT was derived by using a weighted- average cost of capital of 13% for Cassava shares to discount free cash flows from our projection of annual sales of PTI-125 in Alzheimer’s disease, and dividing them by our projected number of shares for each year to account for the effects of share dilution." (8/16/2019)

Has Cassava Sciences been receiving favorable news coverage?

Media coverage about SAVA stock has been trending somewhat negative on Saturday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cassava Sciences earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutCassava Sciences.

Are investors shorting Cassava Sciences?

Cassava Sciences saw a drop in short interest in February. As of February 28th, there was short interest totaling 1,190,000 shares, a drop of 17.4% from the February 13th total of 1,440,000 shares. Based on an average trading volume of 4,960,000 shares, the short-interest ratio is currently 0.2 days. Approximately 8.1% of the shares of the stock are short sold. View Cassava Sciences' Current Options Chain.

Who are some of Cassava Sciences' key competitors?

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Baidu (BIDU), DURECT (DRRX), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP), Bristol-Myers Squibb (BMY), Amarin (AMRN) and TrovaGene (TROV).

Who are Cassava Sciences' key executives?

Cassava Sciences' management team includes the following people:
  • Mr. Remi Barbier, Founder, Chairman, CEO & Pres (Age 59)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 51)
  • Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 76)
  • Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.90%), Geode Capital Management LLC (0.84%), Jefferies Group LLC (0.41%), Marshall Wace LLP (0.32%), Envestnet Asset Management Inc. (0.28%) and Cetera Advisor Networks LLC (0.12%). Company insiders that own Cassava Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, Eric Schoen, Remi Barbier and Sanford Robertson. View institutional ownership trends for Cassava Sciences.

Which major investors are selling Cassava Sciences stock?

SAVA stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. View insider buying and selling activity for Cassava Sciences.

Which major investors are buying Cassava Sciences stock?

SAVA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Jefferies Group LLC, Geode Capital Management LLC, Marshall Wace LLP, Cetera Advisor Networks LLC, Acadian Asset Management LLC, and Jane Street Group LLC. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson. View insider buying and selling activity for Cassava Sciences.

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $4.26.

How big of a company is Cassava Sciences?

Cassava Sciences has a market capitalization of $73.36 million. The company earns $-6,560,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Cassava Sciences employs 9 workers across the globe. View additional information about Cassava Sciences.

What is Cassava Sciences' official website?

The official website for Cassava Sciences is http://www.cassavasciences.com/.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]


MarketBeat Community Rating for Cassava Sciences (NASDAQ SAVA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  95
MarketBeat's community ratings are surveys of what our community members think about Cassava Sciences and other stocks. Vote "Outperform" if you believe SAVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SAVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel